Literature DB >> 32433120

Immediate Impact of Coronavirus Disease 2019 on Electroconvulsive Therapy Practice.

Sally-Anne Colbert1, Shane McCarron1, Geraldine Ryan1, Declan M McLoughlin.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32433120      PMCID: PMC7188035          DOI: 10.1097/YCT.0000000000000688

Source DB:  PubMed          Journal:  J ECT        ISSN: 1095-0680            Impact factor:   3.692


× No keyword cloud information.
We are currently in the early stages of a global pandemic of coronavirus disease 2019 (COVID-19) that will last many months and challenge public health services with major socioeconomic consequences. The mechanisms of the outbreak are not yet fully clear but the responsible novel zoonotic SARS-CoV-2 coronavirus has high transmissibility.[1] COVID-19 is mainly spread by exposure to respiratory droplets from nearby infected persons. These then get into mucosal membranes in the eyes, nose or mouth, either directly or indirectly, e.g. via touching one’s face with a contaminated hand. Symptoms can take up to 14 days to be apparent. Early symptoms include fever, cough and dyspnoea. Most infected persons will have a mild illness and some actually remain asymptomatic. However, 15-20% of those infected will have a severe illness with 5-10% requiring critical care. The mortality rate varies depending on local factors and is about 2%, i.e. about 10 time higher than regular seasonal influenza infections. Older adults and those with pre-existing medical illnesses (e.g. diabetes, malignancy, cardiovascular disease, hypertension, chronic respiratory disease) are at greatest risk of death from COVID-19 with a mortality of around 10%. Interestingly, children are much less susceptible to COVID-19 than adults. No drugs or vaccines are currently available for COVID-19. Hand-washing, respiratory etiquette, social/physical distancing, self-isolation, case detection, contact tracing, quarantining and travel bans are all essential measures to reduce risk of infection and rates of community transmission.[2] Health care workers are at higher risk of exposure due to close contact with infected persons who may be symptomatic or even asymptomatic. When indicated, use of Personal Protective Equipment (PPE) is therefore a key component in mitigating this risk in order to maintain the safety of health care workers, prevent depletion of the health care workforce, and reduce community spread of COVID-19. This risk applies to ECT practitioners as well. ECT involves anaesthesia and non-invasive ventilation with a bag mask, which may not create a perfect seal such as can be controlled with intubation. ECT is therefore a droplet and aerosol-generating procedure. Patients may also require suctioning of airway fluids, creating further opportunity for droplet spread in the treatment room. ECT practitioners need to liaise with their senior anaesthetic colleagues to optimise a safe environment for ECT and determine the most appropriate PPE to be used.[3] This may include protective eyewear, body gowns, headwear, facemasks, shoe covers and gloves (Figure 1). Local protocols should be based on national and international best practice guidance and will also need to include protocols for safe and supervised donning and doffing of PPE. Unfortunately, because of unprecedented demand, PPE gear is becoming a scarce resource and this needs to be factored into clinical decision-making processes, keeping in mind healthcare disparity between countries with high, middle and low incomes.
FIGURE 1

The ECT Team in the St Patrick’s University Hospital ECT Treatment Room are using PPE, including gowns, headgear, masks, goggles and gloves. Nursing staff in the separate ECT Recovery Room are similarly attired.

The ECT Team in the St Patrick’s University Hospital ECT Treatment Room are using PPE, including gowns, headgear, masks, goggles and gloves. Nursing staff in the separate ECT Recovery Room are similarly attired. The COVID pandemic is a rapidly evolving situation and ECT practitioners need to keep abreast of developments and changing policies. Regularly updated information and clinical guidance should be accessed from reputable national and international scientific and medical organisations, e.g. the Health Service Executive in Ireland (https://www2.hse.ie/coronavirus/), the Centers for Disease Control and Prevention (USA; https://www.cdc.gov/coronavirus/2019-ncov/index.html) and the World Health Organisation (https://www.who.int/emergencies/diseases/novel-coronavirus-2019).
  3 in total

1.  Covid-19 and community mitigation strategies in a pandemic.

Authors:  Shahul H Ebrahim; Qanta A Ahmed; Ernesto Gozzer; Patricia Schlagenhauf; Ziad A Memish
Journal:  BMJ       Date:  2020-03-17

2.  Coronavirus Disease 2019 (COVID-19): A critical care perspective beyond China.

Authors:  Jordi Rello; Sofia Tejada; Caroline Userovici; Kostoula Arvaniti; Jérôme Pugin; Grant Waterer
Journal:  Anaesth Crit Care Pain Med       Date:  2020-03-03       Impact factor: 4.132

Review 3.  Can we contain the COVID-19 outbreak with the same measures as for SARS?

Authors:  Annelies Wilder-Smith; Calvin J Chiew; Vernon J Lee
Journal:  Lancet Infect Dis       Date:  2020-03-05       Impact factor: 25.071

  3 in total
  7 in total

1.  Electroconvulsive Therapy in Canada During the First Wave of COVID-19: Results of the "What Happened" National Survey.

Authors:  Ilya Demchenko; Daniel M Blumberger; Alastair J Flint; Melanie Anderson; Zafiris J Daskalakis; Karen Foley; Keyvan Karkouti; Sidney H Kennedy; Karim S Ladha; Jamie Robertson; Alon Vaisman; David Koczerginski; Sagar V Parikh; Venkat Bhat
Journal:  J ECT       Date:  2022-03-01       Impact factor: 3.692

2.  An Online Survey About Electroconvulsive Therapy in Japan During the COVID-19 Pandemic: Comparison of Early and Recent Stages.

Authors:  Risa Hirata; Hirotsugu Kawashima; Takashi Tsuboi; Ken Wada; Minoru Takebayashi; Taro Suwa
Journal:  Neuropsychiatr Dis Treat       Date:  2022-06-28       Impact factor: 2.989

3.  Psychotropics and COVID-19: An analysis of safety and prophylaxis.

Authors:  H Javelot; C Straczek; G Meyer; C Gitahy Falcao Faria; L Weiner; D Drapier; E Fakra; P Fossati; S Weibel; S Dizet; B Langrée; M Masson; R Gaillard; M Leboyer; P M Llorca; C Hingray; E Haffen; A Yrondi
Journal:  Encephale       Date:  2021-09-02       Impact factor: 1.291

4.  Ect in Two Elderly Patients with Covid-19: Weighing Up Unknown Risks in Unprecedented Times.

Authors:  Robyn H McCarron; Ruchika Rathee; Sharon Yang; Chandran Thavachelvi
Journal:  Clin Neuropsychiatry       Date:  2020-10

Review 5.  The Impact of COVID-19 on Brain Stimulation Therapy.

Authors:  Michael Justin Coffey; Suzanne Kerns; Sohag Sanghani; Lee Wachtel
Journal:  Psychiatr Clin North Am       Date:  2021-11-16

6.  "ECT should never stop": Exploring the experiences and recommendations of ECT clinical directors and anesthetists about ECT during the COVID-19 pandemic.

Authors:  Grace Branjerdporn; Shanthi Sarma; Laura McCosker; Vanessa Dong; Donel Martin; Colleen Loo
Journal:  Front Psychiatry       Date:  2022-09-14       Impact factor: 5.435

7.  Access barriers to electroconvulsive therapy during COVID-19 pandemic.

Authors:  Hernández-Huerta Daniel; Alonso-Sánchez Elena Begoña
Journal:  Psychiatry Res       Date:  2020-05-06       Impact factor: 11.225

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.